Article Abstract

Erlotinib as standard adjuvant therapy for resectable EGFR mutation-positive non-small cell lung cancer

Authors: Satomi Tanaka, Junji Uchino

Abstract

This Chinese randomized, open-label, phase 2 trial compared erlotinib with the standard-of-care vinorelbine plus cisplatin therapy as adjuvant treatment for patients with stage IIIA EGFR mutation-positive non-small cell lung cancer (NSCLC) who were able to undergo complete resection.

Article Options

Download Citation